Molbio Diagnostics IPO Lists Today: Potential 16.11% Gain

Molbio Diagnostics IPO is hitting the market today, August 17, 2026, with investors looking at a potential 16.11% listing gain. The grey market premium (GMP) sits at Rs 130, pushing the estimated listing price to Rs 937.

Subscription Overview

This IPO saw massive investor interest, subscribed 70.26 times overall.

• Qualified Institutional Buyers (QIBs) went big, subscribing 186.39 times.
• Non-Institutional Investors (NIIs) hit 49.80 times.
• Retail Individual Investors (RIIs) reached 12.96 times.

Issue Details

The Rs 939.70 crore book-built issue offered 81.59 lakh shares.

• It included a fresh issue of 25 lakh shares worth Rs 200 crore.
• An offer-for-sale (OFS) covered 92 lakh shares valued at Rs 739.70 crore.
• The price band was set between Rs 768 and Rs 807 per share, with a lot size of 18 shares. Retail investors needed a minimum Rs 14,526.

Expansion Strategy

Molbio Diagnostics, founded in October 2000, is known for its proprietary Truenat platform in molecular diagnostics. The company plans significant expansion using the IPO funds.

• Establishing new research and development infrastructure.
• Setting up a Center of Excellence and connected office space.
• Allocating Rs 80.81 crore for equipment across its Goa Unit I, Goa Unit II, and Visakhapatnam Unit. Remaining funds are for general corporate purposes.

Financial Performance

For FY26, Molbio Diagnostics reported a total income of Rs 1,455.17 crore. Profit after tax for the same period stood at Rs 164.14 crore.